Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project

Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project

Background and aim: Disease-modifying therapies (DMTs) used in multiple sclerosis (MS) have distinct safety profiles. In this paper, we report preliminary results of an on-going pharmacovigilance project (the FASM study). Results: Neurologists working at involved multiple sclerosis centers collected...

Full description

Bibliographic Details
Main Authors: Giorgia Teresa Maniscalco, Vincenzo Brescia Morra, Ciro Florio, Giacomo Lus, Gioacchino Tedeschi, Maddalena Cianfrani, Renato Docimo, Stefania Miniello, Felice Romano, Leonardo Sinisi, Daniele L. A. Spitaleri, Giuseppe Longo, Ugo Trama, Maria Triassi, FASM Group, Cristina Scavone, Annalisa Capuano
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Pharmaceuticals
Subjects:
multiple sclerosis
disease-modifying therapies
safety
adverse drugs reactions
FASM study
pharmacovigilance project
Online Access:https://www.mdpi.com/1424-8247/13/12/466

Internet

https://www.mdpi.com/1424-8247/13/12/466

Similar Items